Stevenage, United Kingdom

Katherine (Nee Sully) Nevin


Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Katherine (Nee Sully) Nevin

Introduction

Katherine (Nee Sully) Nevin, an accomplished inventor based in Stevenage, GB, is recognized for her significant contributions to the field of biotechnology. With a deep commitment to improving healthcare outcomes, Katherine has focused her research on multiple myeloma, a type of cancer that affects plasma cells.

Latest Patents

Katherine holds a crucial patent that outlines a prognostic method for determining the prognosis of multiple myeloma in patients. This innovative method involves measuring the expression of B-cell maturation antigen (BCMA) in a sample. Additionally, her patent includes methods for treating multiple myeloma by administering an effective amount of an antigen-binding protein that targets BCMA. The patent also details the development of kits designed for measuring BCMA expression in biological samples, providing essential tools for clinical assessment and treatment.

Career Highlights

Katherine is currently employed at GlaxoSmithKline Intellectual Property Development Limited, a leading global healthcare company that aims to help people do more, feel better, and live longer. Throughout her career, she has demonstrated a strong aptitude for merging science with practical applications, contributing to advancements in therapeutic strategies for cancer treatment.

Collaborations

In her professional journey, Katherine has worked alongside esteemed colleagues, including Danton Bounds and Jenny L. Craigen. These collaborations have enabled her to leverage a diverse range of expertise, fostering an environment of innovation and excellence in research.

Conclusion

Katherine (Nee Sully) Nevin exemplifies the impact of dedicated inventors in the medical field. Her pioneering work in the prognosis and treatment of multiple myeloma through innovative methods and tools continues to enhance the landscape of cancer research and therapy. As she progresses in her career, Katherine remains a vital figure in the quest for improved healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…